Condition: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia · Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.
This description comes directly from the study's public registry record.
Jing Chen · 0086-021-38626161 · chenjing@scmc.com.cn
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital | Beijing, China | Recruiting |
| Jiangxi Province pediatric hospital | Nanchang, China | Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, China | Recruiting |
| Children's Hospital of Shanghai | Shanghai, China | Recruiting |
| Shanghai Children's Medical Center | Shanghai, China | Recruiting |
| Children's Hospital of Soochow University | Suzhou, China | Recruiting |
| Tongji Hospital | Wuhan, China | Recruiting |
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06927466